Clinical-Epidemiology Aspect of Inpatients With Moderate or Severe COVID-19 in a Brazilian Macroregion: Disease and Countermeasures
et al., Frontiers in Cellular and Infection Microbiology,
Retrospective 395 hospitalized patients in Brazil, showing mortality HR 0.59 for antiparasitic use, however there were only 8 patients treated and authors do not distinguish between albendazole and ivermectin.
risk of death, 32.3% lower, RR 0.68, p = 0.57, treatment 8, control 387, adjusted per study, odds ratio converted to relative risk, ivermectin or albendazole, multivariable, control prevalance approximated with overall prevalence.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Silva et al., 20 May 2022, retrospective, Brazil, peer-reviewed, mean age 58.4, 28 authors, study period 25 March, 2020 - 21 October, 2020.